Cognitive complaints by hematopoietic cell transplantation recipients and change in neuropsychological performance over time.
Adult
Anxiety
/ psychology
Attention
Cognition
/ physiology
Cognitive Dysfunction
/ psychology
Cross-Sectional Studies
Female
Hematopoietic Stem Cell Transplantation
/ psychology
Humans
Longitudinal Studies
Male
Memory, Short-Term
/ physiology
Middle Aged
Neuropsychological Tests
Psychometrics
/ methods
Quality of Life
/ psychology
Self Report
Self-Assessment
Surveys and Questionnaires
Transplant Recipients
/ psychology
Cancer
Cognition
Cognitive dysfunction
Hematopoietic stem cell transplantation
Neuropsychological tests
Oncology
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
18
12
2019
accepted:
04
04
2020
pubmed:
30
4
2020
medline:
15
12
2020
entrez:
30
4
2020
Statut:
ppublish
Résumé
Hematopoietic stem cell transplant (HSCT) recipients are at risk for cognitive decline. Cross-sectional studies show patients' complaints of cognitive decline do not correlate well with concurrently measured objective neuropsychological performance, but rather with emotional variables and health-related quality of life. This longitudinal study investigated whether patient self-report of cognitive status would be concordant with objectively measured neuropsychological performance after accounting for change from their own pre-transplant objective baseline. Pre-HSCT and at 30 and 100 days post-HSCT, 46 patients underwent computerized neuropsychological testing (CogState) and completed surveys assessing patient-reported cognitive complaints, emotional symptoms (depression, anxiety), sleep quality, daytime sleepiness, and physical and functional well-being. Correlations were calculated between cognitive complaints and neuropsychological performance (at each time-point and across time-points), as well as all other patient-reported variables. Patient-reported cognitive complaints were largely independent of concurrently assessed objective neuropsychological performance. Uniquely, our longitudinal data demonstrated significant medium to large effect size associations between subjective cognitive complaints post-HSCT with objectively measured change from pre-HSCT in attention, visual learning, and working memory (p < .05-.01). Subjective cognitive complaints post-HSCT were also associated with depression, anxiety, daytime sleepiness and physical well-being (p < .05-.001). Patients appear better able to assess their cognitive functioning relative to their own baseline and changes across time rather than relative to community norms. Thus, patient complaints of cognitive compromise justify further in-depth neuropsychological, emotional, and functional assessment. Future research into relationships between cognitive complaints and neuropsychological performance should account for changes in performance over time.
Identifiants
pubmed: 32346799
doi: 10.1007/s00520-020-05458-1
pii: 10.1007/s00520-020-05458-1
pmc: PMC7606345
mid: NIHMS1589052
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-254Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR000043
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA198776
Pays : United States
Organisme : NIH HHS
ID : R21CA198776
Pays : United States
Organisme : Blue Cross Blue Shield of Michigan Foundation
ID : 2193.11
Organisme : Gateway for Cancer Research (US)
ID : G-15-200
Organisme : Michigan Institute for Clinical and Health Research
ID : UL1TR00043
Organisme : NIH HHS
ID : R21CA198776
Pays : United States
Références
Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H (2018) Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant 53:535–555
doi: 10.1038/s41409-017-0055-7
Syrjala KL, Artherholt SB, Kurland BF, Langer SL, Roth-Roemer S, Elrod JB, Dikmen S (2011) Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol 29:2397–2404
doi: 10.1200/JCO.2010.33.9119
Sharafeldin N, Bosworth A, Patel SK, Chen Y, Morse E, Mather M, Sun C, Francisco L, Forman SJ, Wong FL, Bhatia S (2017) Cognitive functioning after hematopoietic cell transplantation for hematologic malignancy: results from a prospective longitudinal study. J Clin Oncol 36:463–475
doi: 10.1200/JCO.2017.74.2270
Mayo S, Messner HA, Rourke SB, Howell D, Victor JC, Kuruvilla J, Lipton JH, Gupta V, Kim DD, Piescic C, Breen D (2016) Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation. Bone Marrow Transplant 51:841–847
doi: 10.1038/bmt.2016.2
Booth-Jones M, Jacobsen PB, Ransom S, Soety E (2005) Characteristics and correlates of cognitive functioning following bone marrow transplantation. Bone Marrow Transplant 36:695–702
doi: 10.1038/sj.bmt.1705108
Harder H, Cornelissen JJ, Van Gool AR, Duivenvoorden HJ, Eijkenboom WM, van den Bent MJ (2002) Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation. Cancer 95:183–192
doi: 10.1002/cncr.10627
Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, Okamoto S, Seber A (2012) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther 5:1–30
doi: 10.5144/1658-3876.2012.1
Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP, Hoodin F, Johnston L, Lawitschka A, McDonald GB, Opipari AW (2015) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant 21:1167–1187
doi: 10.1016/j.bbmt.2015.03.024
Jacobs SR, Jacobsen PB, Booth-Jones M, Wagner LI, Anasetti C (2007) Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. J Pain Symptom Manag 33:13–23
doi: 10.1016/j.jpainsymman.2006.06.011
Ghazikhanian SE, Dorfman CS, Somers TJ, O'Sullivan ML, Fisher HM, Edmond SN, Wren AA, Kelleher SA, Nichols KR, Chao N, Shelby RA (2017) Cognitive problems following hematopoietic stem cell transplant: relationships with sleep, depression and fatigue. Bone Marrow Transplant 52:279–284
doi: 10.1038/bmt.2016.248
Bray VJ, Dhillon HM, Vardy JL (2018) Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment. J Cancer Surviv 12:537–559
doi: 10.1007/s11764-018-0692-x
Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38:926–934
doi: 10.1016/j.ctrv.2012.05.002
Wagner L, Sweet JJ, Butt Z, Lai J, Cella D (2009) Measuring patient self-reported cognitive function: qualitative findings and initial development of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-COG) instrument. J Support Oncol 7:W32–W39
Costa DS, Fardell JE (2019) Why are objective and perceived cognitive function weakly correlated in patients with cancer? J Clin Oncol 37:1154–1158
doi: 10.1200/JCO.18.02363
Collins B, Paquet L, Dominelli R, White A, MacKenzie J (2017) Metamemory function in chemotherapy-treated patients with breast cancer: an explanation for the dissociation between subjective and objective memory measures. Psycho-oncology 26:109–117
doi: 10.1002/pon.4012
Hoodin F, LaLonde L, Errickson J, Votruba K, Kentor R, Gatza E, Reddy P, Choi SW (2019) Cognitive function and quality of life in vorinostat-treated patients after matched unrelated donor myeloablative conditioning hematopoietic cell transplantation. Biol Blood Marrow Tr 25:343–353
doi: 10.1016/j.bbmt.2018.09.015
Collie A, Darekar A, Weissgerber G, Toh MK, Snyder PJ, Maruff P, Huggins JP (2007) Cognitive testing in early-phase clinical trials: development of a rapid computerized test battery and application in a simulated phase I study. Contemp Clin Trials 28:391–400
doi: 10.1016/j.cct.2006.10.010
Hammers D, Spurgeon E, Ryan K, Persad C, Barbas N, Heidebrink J, Darby D, Giordani B (2012) Validity of a brief computerized cognitive screening test in dementia. J Geriatr Psychiatry Neurol 25:89–99
doi: 10.1177/0891988712447894
Spitzer RL, Kroenke K, Williams JB (1999) Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders Patient Health Questionnaire. JAMA 282:1737–1744
doi: 10.1001/jama.282.18.1737
Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16:606–613
doi: 10.1046/j.1525-1497.2001.016009606.x
Spitzer RL, Kroenke K, Williams JB, Lowe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166:1092–1097. https://doi.org/10.1001/archinte.166.10.1092
doi: 10.1001/archinte.166.10.1092
Plummer F, Manea L, Trepel D, McMillan D (2016) Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry 39:24–31. https://doi.org/10.1016/j.genhosppsych.2015.11.005
doi: 10.1016/j.genhosppsych.2015.11.005
pubmed: 26719105
Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. J Psychiatr Res 28:193–213
doi: 10.1016/0165-1781(89)90047-4
Carpenter JS, Andrykowski MA (1998) Psychometric evaluation of the Pittsburgh sleep quality index. J Psychosom Res 45:5–13
doi: 10.1016/S0022-3999(97)00298-5
Buysse DJ, Hall ML, Strollo PJ, Kamarck TW, Owens J, Lee L, Reis SE, Matthews KA (2008) Relationships between the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and clinical/polysomnographic measures in a community sample. J Clin Sleep Med 4:563–571
doi: 10.5664/jcsm.27351
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, Eckberg K (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579. https://doi.org/10.1200/JCO.1993.11.3.570
doi: 10.1200/JCO.1993.11.3.570
pubmed: 8445433
IBM Corp. Released 2016. IBM SPSS Statistics for Windows, Version 24.0. IBM Corp, Armonk, NY
Cohen J (1992) A power primer. Psychol Bull 112:155–159. https://doi.org/10.1037/0033-2909.112.1.155
doi: 10.1037/0033-2909.112.1.155
pubmed: 19565683
Ganz PA, Petersen L, Castellon SA, Bower JE, Silverman DH, Cole SW, Irwin MR, Belin TR (2014) Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study. J Clin Oncol 32:3559–3567
doi: 10.1200/JCO.2014.56.1662